Global Cancer Monoclonal Antibody Partnering Terms and Agreements Deal Trends, Players and Financials Report 2016

Mar 21, 2016, 11:10 ET from Research and Markets

DUBLIN, March 21, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials"  report to their offering.

     (Logo: )

The Global Cancer Monoclonal Antibody Partnering 2010-2016: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. 

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. 

This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. 

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering: 

  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:  

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target
  • Monoclonal antibody type

Key Topics Covered: 

Executive Summary 

Chapter 1 - Introduction 

Chapter 2 - Trends in Cancer monoclonal antibody dealmaking 

Chapter 3 - Leading Cancer monoclonal antibody deals 

Chapter 4 - Most active Cancer monoclonal antibody dealmakers 

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory 

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type 

Chapter 7 - Partnering resource center 

For more information visit

Media Contact:
Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets